Global Rare Disease Treatment Market
Global Rare Disease Treatment Market

Rare Disease Treatment Comprehensive Study by Application (Hospitals, Clinics, Others), Drug Type (Originator, Generic), Distribution Channel (Pharmacies, Direct Marketing Routes, Convenience Stores, Online, Others), Form (Tablet, Powder, Injections, Others), Therapeutic Area (Oncology, Hematology, Inflammatory Disease, Endocrine Disease, Metabolic Disease, Infectious Disease, Neurological Disease, Skin Disease, Pulmonary Disease, Kidney Disease, Musculoskeletal Disease) Players and Region - Global Market Outlook to 2024

Rare Disease Treatment Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

Apr 2020 Edition 208 Pages 210 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Rare Disease Treatment Market Scope
A rare disease is a group of conditions that affect very small numbers of people. Rare diseases affect approximately 6-10% of the population and 3-4% of births. It tends to be severe, chronic conditions and in many cases, they are progressive, debilitating, and life-threatening. Patient access to the treatment, including medicines, is access to healthcare professionals and a healthcare infrastructure that fosters the correct diagnosis. On average, a treatment for a rare disease costs USD137,000 per person per year. According to the WHO, rare diseases range from cystic fibrosis and haemophilia to angelman syndrome, with an incidence of about 1 in 15 000, to Opitz trigonocephaly syndrome. It is extremely rare with about one case per million people. Most people suffering from rare diseases do not have any treatment options available for their condition. (It is estimated that 95% of rare diseases do not have a treatment option.) In March 2020, FDA grants experimental coronavirus drug benefits for rare disease treatments.

The market study is segmented, by Application (Hospitals, Clinics and Others) and major geographies with country level break-up.

Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Rare Disease Treatment market throughout the predicted period.

Novartis (Switzerland), Pfizer, Inc. (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Celgene Corporation (United States), Alexion Pharmaceuticals, Inc. (United States), Johnson & Johnson (United States), Novo Nordisk A/S (Denmark), Sanofi S.A. (France), Bayer AG (Germany), GlaxoSmithKline (United Kingdom), Allergan (Ireland), Eli Lilly and Company (United States), Eisai Co., Ltd. (Japan), Bristol-Myers Squibb and Merck & Co., Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Bristol-Myers Squibb Company (United States), AstraZeneca (United Kingdom), Daiichi Sankyo Company Limited (Japan), Biogen, Inc. (United States), Shire Plc (United States), Alexion Pharmaceuticals (United States), Amgen Inc. (United States), Vertex Pharmaceuticals (United States), Baxter International Inc.. (United States), BioMarin (United States) and Teva Pharmaceutical Industries (Isreal).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Rare Disease Treatment market by Type, Application and Region.

On the basis of geography, the market of Rare Disease Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Leaders and their expansionary development strategies
In Feb 2019, Ipsen announced the acquisition of the Clementia Pharmaceuticals for the treatment of the key late-stage clinical asset palovarotene, multiple osteochondromas, and others. Through this agreement, the company is aiming to enhance its product portfolio in rare diseases across the globe.



Market Trend
  • Growing Research Activities and the Increasing focus on the Development of New Therapeutics and Drugs
  • Sustainable Access to Diagnosis, Treatment
  • and Care

Market Drivers
  • Increasing Geriatric Population and the Rising Focus of the Players on the Enhancement of the Medical Facilities
  • Rising Awareness among People about Efficient Treatment Methods to Treat Rare Diseases

Opportunities
  • Greater Collaboration at all Levels Will Help Drive Research
  • and Improve Care
  • Rising Investment of Research and Development on the Rare Disease Treatments

Restraints
  • Delays and Frequent Errors in Diagnosis, often with Severe Consequences for Patient Outcomes

Challenges
  • Rare diseases pose challenges for research and clinical development due to the small numbers of patients, limited epidemiological data on the natural history of many rare diseases, and all stages of research and development being more challenging and lengthy than for more
  • common diseases.
  • Lack of Skilled Healthcare Personnel


Key Target Audience
Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Rare Disease Drug Manufacturers, Suppliers and Distributors, Raw Material Suppliers, Government Regulatory and Research Organizations and End-Use Industries

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Application
  • Hospitals
  • Clinics
  • Others
By Drug Type
  • Originator
  • Generic

By Distribution Channel
  • Pharmacies
  • Direct Marketing Routes
  • Convenience Stores
  • Online
  • Others

By Form
  • Tablet
  • Powder
  • Injections
  • Others

By Therapeutic Area
  • Oncology
  • Hematology
  • Inflammatory Disease
  • Endocrine Disease
  • Metabolic Disease
  • Infectious Disease
  • Neurological Disease
  • Skin Disease
  • Pulmonary Disease
  • Kidney Disease
  • Musculoskeletal Disease

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Geriatric Population and the Rising Focus of the Players on the Enhancement of the Medical Facilities
      • 3.2.2. Rising Awareness among People about Efficient Treatment Methods to Treat Rare Diseases
    • 3.3. Market Challenges
      • 3.3.1. Rare diseases pose challenges for research and clinical development due to the small numbers of patients, limited epidemiological data on the natural history of many rare diseases, and all stages of research and development being more challenging and lengthy than for more
      • 3.3.2. Common diseases.
      • 3.3.3. Lack of Skilled Healthcare Personnel
    • 3.4. Market Trends
      • 3.4.1. Growing Research Activities and the Increasing focus on the Development of New Therapeutics and Drugs
      • 3.4.2. Sustainable Access to Diagnosis, Treatment
      • 3.4.3. And Care
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Rare Disease Treatment, by Application, Drug Type, Distribution Channel , Form, Therapeutic Area and Region (value, volume and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Rare Disease Treatment (Value)
      • 5.2.1. Global Rare Disease Treatment by: Application (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Clinics
        • 5.2.1.3. Others
      • 5.2.2. Global Rare Disease Treatment by: Drug Type (Value)
        • 5.2.2.1. Originator
        • 5.2.2.2. Generic
      • 5.2.3. Global Rare Disease Treatment by: Form (Value)
        • 5.2.3.1. Tablet
        • 5.2.3.2. Powder
        • 5.2.3.3. Injections
        • 5.2.3.4. Others
      • 5.2.4. Global Rare Disease Treatment by: Therapeutic Area (Value)
        • 5.2.4.1. Oncology
        • 5.2.4.2. Hematology
        • 5.2.4.3. Inflammatory Disease
        • 5.2.4.4. Endocrine Disease
        • 5.2.4.5. Metabolic Disease
        • 5.2.4.6. Infectious Disease
        • 5.2.4.7. Neurological Disease
        • 5.2.4.8. Skin Disease
        • 5.2.4.9. Pulmonary Disease
        • 5.2.4.10. Kidney Disease
        • 5.2.4.11. Musculoskeletal Disease
      • 5.2.5. Global Rare Disease Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Rare Disease Treatment (Volume)
      • 5.3.1. Global Rare Disease Treatment by: Application (Volume)
        • 5.3.1.1. Hospitals
        • 5.3.1.2. Clinics
        • 5.3.1.3. Others
      • 5.3.2. Global Rare Disease Treatment by: Drug Type (Volume)
        • 5.3.2.1. Originator
        • 5.3.2.2. Generic
      • 5.3.3. Global Rare Disease Treatment by: Form (Volume)
        • 5.3.3.1. Tablet
        • 5.3.3.2. Powder
        • 5.3.3.3. Injections
        • 5.3.3.4. Others
      • 5.3.4. Global Rare Disease Treatment by: Therapeutic Area (Volume)
        • 5.3.4.1. Oncology
        • 5.3.4.2. Hematology
        • 5.3.4.3. Inflammatory Disease
        • 5.3.4.4. Endocrine Disease
        • 5.3.4.5. Metabolic Disease
        • 5.3.4.6. Infectious Disease
        • 5.3.4.7. Neurological Disease
        • 5.3.4.8. Skin Disease
        • 5.3.4.9. Pulmonary Disease
        • 5.3.4.10. Kidney Disease
        • 5.3.4.11. Musculoskeletal Disease
      • 5.3.5. Global Rare Disease Treatment Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Rare Disease Treatment (Price)
  • 6. Rare Disease Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Celgene Corporation (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Alexion Pharmaceuticals, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Johnson & Johnson (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Novo Nordisk A/S (Denmark)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sanofi S.A. (France)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bayer AG (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. GlaxoSmithKline (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Allergan (Ireland)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Eli Lilly and Company (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Eisai Co., Ltd. (Japan)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Bristol-Myers Squibb
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Merck & Co., Inc. (United States)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
  • 7. Global Rare Disease Treatment Sale, by Application, Drug Type, Distribution Channel , Form, Therapeutic Area and Region (value, volume and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Rare Disease Treatment (Value)
      • 7.2.1. Global Rare Disease Treatment by: Application (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Clinics
        • 7.2.1.3. Others
      • 7.2.2. Global Rare Disease Treatment by: Drug Type (Value)
        • 7.2.2.1. Originator
        • 7.2.2.2. Generic
      • 7.2.3. Global Rare Disease Treatment by: Form (Value)
        • 7.2.3.1. Tablet
        • 7.2.3.2. Powder
        • 7.2.3.3. Injections
        • 7.2.3.4. Others
      • 7.2.4. Global Rare Disease Treatment by: Therapeutic Area (Value)
        • 7.2.4.1. Oncology
        • 7.2.4.2. Hematology
        • 7.2.4.3. Inflammatory Disease
        • 7.2.4.4. Endocrine Disease
        • 7.2.4.5. Metabolic Disease
        • 7.2.4.6. Infectious Disease
        • 7.2.4.7. Neurological Disease
        • 7.2.4.8. Skin Disease
        • 7.2.4.9. Pulmonary Disease
        • 7.2.4.10. Kidney Disease
        • 7.2.4.11. Musculoskeletal Disease
      • 7.2.5. Global Rare Disease Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Rare Disease Treatment (Volume)
      • 7.3.1. Global Rare Disease Treatment by: Application (Volume)
        • 7.3.1.1. Hospitals
        • 7.3.1.2. Clinics
        • 7.3.1.3. Others
      • 7.3.2. Global Rare Disease Treatment by: Drug Type (Volume)
        • 7.3.2.1. Originator
        • 7.3.2.2. Generic
      • 7.3.3. Global Rare Disease Treatment by: Form (Volume)
        • 7.3.3.1. Tablet
        • 7.3.3.2. Powder
        • 7.3.3.3. Injections
        • 7.3.3.4. Others
      • 7.3.4. Global Rare Disease Treatment by: Therapeutic Area (Volume)
        • 7.3.4.1. Oncology
        • 7.3.4.2. Hematology
        • 7.3.4.3. Inflammatory Disease
        • 7.3.4.4. Endocrine Disease
        • 7.3.4.5. Metabolic Disease
        • 7.3.4.6. Infectious Disease
        • 7.3.4.7. Neurological Disease
        • 7.3.4.8. Skin Disease
        • 7.3.4.9. Pulmonary Disease
        • 7.3.4.10. Kidney Disease
        • 7.3.4.11. Musculoskeletal Disease
      • 7.3.5. Global Rare Disease Treatment Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Rare Disease Treatment (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Rare Disease Treatment: by Application(USD Million)
  • Table 2. Rare Disease Treatment Hospitals , by Region USD Million (2013-2018)
  • Table 3. Rare Disease Treatment Clinics , by Region USD Million (2013-2018)
  • Table 4. Rare Disease Treatment Others , by Region USD Million (2013-2018)
  • Table 5. Rare Disease Treatment: by Drug Type(USD Million)
  • Table 6. Rare Disease Treatment Originator , by Region USD Million (2013-2018)
  • Table 7. Rare Disease Treatment Generic , by Region USD Million (2013-2018)
  • Table 8. Rare Disease Treatment: by Form(USD Million)
  • Table 9. Rare Disease Treatment Tablet , by Region USD Million (2013-2018)
  • Table 10. Rare Disease Treatment Powder , by Region USD Million (2013-2018)
  • Table 11. Rare Disease Treatment Injections , by Region USD Million (2013-2018)
  • Table 12. Rare Disease Treatment Others , by Region USD Million (2013-2018)
  • Table 13. Rare Disease Treatment: by Therapeutic Area(USD Million)
  • Table 14. Rare Disease Treatment Oncology , by Region USD Million (2013-2018)
  • Table 15. Rare Disease Treatment Hematology , by Region USD Million (2013-2018)
  • Table 16. Rare Disease Treatment Inflammatory Disease , by Region USD Million (2013-2018)
  • Table 17. Rare Disease Treatment Endocrine Disease , by Region USD Million (2013-2018)
  • Table 18. Rare Disease Treatment Metabolic Disease , by Region USD Million (2013-2018)
  • Table 19. Rare Disease Treatment Infectious Disease , by Region USD Million (2013-2018)
  • Table 20. Rare Disease Treatment Neurological Disease , by Region USD Million (2013-2018)
  • Table 21. Rare Disease Treatment Skin Disease , by Region USD Million (2013-2018)
  • Table 22. Rare Disease Treatment Pulmonary Disease , by Region USD Million (2013-2018)
  • Table 23. Rare Disease Treatment Kidney Disease , by Region USD Million (2013-2018)
  • Table 24. Rare Disease Treatment Musculoskeletal Disease , by Region USD Million (2013-2018)
  • Table 25. South America Rare Disease Treatment, by Country USD Million (2013-2018)
  • Table 26. South America Rare Disease Treatment, by Application USD Million (2013-2018)
  • Table 27. South America Rare Disease Treatment, by Drug Type USD Million (2013-2018)
  • Table 28. South America Rare Disease Treatment, by Distribution Channel USD Million (2013-2018)
  • Table 29. South America Rare Disease Treatment, by Form USD Million (2013-2018)
  • Table 30. South America Rare Disease Treatment, by Therapeutic Area USD Million (2013-2018)
  • Table 31. Brazil Rare Disease Treatment, by Application USD Million (2013-2018)
  • Table 32. Brazil Rare Disease Treatment, by Drug Type USD Million (2013-2018)
  • Table 33. Brazil Rare Disease Treatment, by Distribution Channel USD Million (2013-2018)
  • Table 34. Brazil Rare Disease Treatment, by Form USD Million (2013-2018)
  • Table 35. Brazil Rare Disease Treatment, by Therapeutic Area USD Million (2013-2018)
  • Table 36. Argentina Rare Disease Treatment, by Application USD Million (2013-2018)
  • Table 37. Argentina Rare Disease Treatment, by Drug Type USD Million (2013-2018)
  • Table 38. Argentina Rare Disease Treatment, by Distribution Channel USD Million (2013-2018)
  • Table 39. Argentina Rare Disease Treatment, by Form USD Million (2013-2018)
  • Table 40. Argentina Rare Disease Treatment, by Therapeutic Area USD Million (2013-2018)
  • Table 41. Rest of South America Rare Disease Treatment, by Application USD Million (2013-2018)
  • Table 42. Rest of South America Rare Disease Treatment, by Drug Type USD Million (2013-2018)
  • Table 43. Rest of South America Rare Disease Treatment, by Distribution Channel USD Million (2013-2018)
  • Table 44. Rest of South America Rare Disease Treatment, by Form USD Million (2013-2018)
  • Table 45. Rest of South America Rare Disease Treatment, by Therapeutic Area USD Million (2013-2018)
  • Table 46. Asia Pacific Rare Disease Treatment, by Country USD Million (2013-2018)
  • Table 47. Asia Pacific Rare Disease Treatment, by Application USD Million (2013-2018)
  • Table 48. Asia Pacific Rare Disease Treatment, by Drug Type USD Million (2013-2018)
  • Table 49. Asia Pacific Rare Disease Treatment, by Distribution Channel USD Million (2013-2018)
  • Table 50. Asia Pacific Rare Disease Treatment, by Form USD Million (2013-2018)
  • Table 51. Asia Pacific Rare Disease Treatment, by Therapeutic Area USD Million (2013-2018)
  • Table 52. China Rare Disease Treatment, by Application USD Million (2013-2018)
  • Table 53. China Rare Disease Treatment, by Drug Type USD Million (2013-2018)
  • Table 54. China Rare Disease Treatment, by Distribution Channel USD Million (2013-2018)
  • Table 55. China Rare Disease Treatment, by Form USD Million (2013-2018)
  • Table 56. China Rare Disease Treatment, by Therapeutic Area USD Million (2013-2018)
  • Table 57. Japan Rare Disease Treatment, by Application USD Million (2013-2018)
  • Table 58. Japan Rare Disease Treatment, by Drug Type USD Million (2013-2018)
  • Table 59. Japan Rare Disease Treatment, by Distribution Channel USD Million (2013-2018)
  • Table 60. Japan Rare Disease Treatment, by Form USD Million (2013-2018)
  • Table 61. Japan Rare Disease Treatment, by Therapeutic Area USD Million (2013-2018)
  • Table 62. India Rare Disease Treatment, by Application USD Million (2013-2018)
  • Table 63. India Rare Disease Treatment, by Drug Type USD Million (2013-2018)
  • Table 64. India Rare Disease Treatment, by Distribution Channel USD Million (2013-2018)
  • Table 65. India Rare Disease Treatment, by Form USD Million (2013-2018)
  • Table 66. India Rare Disease Treatment, by Therapeutic Area USD Million (2013-2018)
  • Table 67. South Korea Rare Disease Treatment, by Application USD Million (2013-2018)
  • Table 68. South Korea Rare Disease Treatment, by Drug Type USD Million (2013-2018)
  • Table 69. South Korea Rare Disease Treatment, by Distribution Channel USD Million (2013-2018)
  • Table 70. South Korea Rare Disease Treatment, by Form USD Million (2013-2018)
  • Table 71. South Korea Rare Disease Treatment, by Therapeutic Area USD Million (2013-2018)
  • Table 72. Taiwan Rare Disease Treatment, by Application USD Million (2013-2018)
  • Table 73. Taiwan Rare Disease Treatment, by Drug Type USD Million (2013-2018)
  • Table 74. Taiwan Rare Disease Treatment, by Distribution Channel USD Million (2013-2018)
  • Table 75. Taiwan Rare Disease Treatment, by Form USD Million (2013-2018)
  • Table 76. Taiwan Rare Disease Treatment, by Therapeutic Area USD Million (2013-2018)
  • Table 77. Australia Rare Disease Treatment, by Application USD Million (2013-2018)
  • Table 78. Australia Rare Disease Treatment, by Drug Type USD Million (2013-2018)
  • Table 79. Australia Rare Disease Treatment, by Distribution Channel USD Million (2013-2018)
  • Table 80. Australia Rare Disease Treatment, by Form USD Million (2013-2018)
  • Table 81. Australia Rare Disease Treatment, by Therapeutic Area USD Million (2013-2018)
  • Table 82. Rest of Asia-Pacific Rare Disease Treatment, by Application USD Million (2013-2018)
  • Table 83. Rest of Asia-Pacific Rare Disease Treatment, by Drug Type USD Million (2013-2018)
  • Table 84. Rest of Asia-Pacific Rare Disease Treatment, by Distribution Channel USD Million (2013-2018)
  • Table 85. Rest of Asia-Pacific Rare Disease Treatment, by Form USD Million (2013-2018)
  • Table 86. Rest of Asia-Pacific Rare Disease Treatment, by Therapeutic Area USD Million (2013-2018)
  • Table 87. Europe Rare Disease Treatment, by Country USD Million (2013-2018)
  • Table 88. Europe Rare Disease Treatment, by Application USD Million (2013-2018)
  • Table 89. Europe Rare Disease Treatment, by Drug Type USD Million (2013-2018)
  • Table 90. Europe Rare Disease Treatment, by Distribution Channel USD Million (2013-2018)
  • Table 91. Europe Rare Disease Treatment, by Form USD Million (2013-2018)
  • Table 92. Europe Rare Disease Treatment, by Therapeutic Area USD Million (2013-2018)
  • Table 93. Germany Rare Disease Treatment, by Application USD Million (2013-2018)
  • Table 94. Germany Rare Disease Treatment, by Drug Type USD Million (2013-2018)
  • Table 95. Germany Rare Disease Treatment, by Distribution Channel USD Million (2013-2018)
  • Table 96. Germany Rare Disease Treatment, by Form USD Million (2013-2018)
  • Table 97. Germany Rare Disease Treatment, by Therapeutic Area USD Million (2013-2018)
  • Table 98. France Rare Disease Treatment, by Application USD Million (2013-2018)
  • Table 99. France Rare Disease Treatment, by Drug Type USD Million (2013-2018)
  • Table 100. France Rare Disease Treatment, by Distribution Channel USD Million (2013-2018)
  • Table 101. France Rare Disease Treatment, by Form USD Million (2013-2018)
  • Table 102. France Rare Disease Treatment, by Therapeutic Area USD Million (2013-2018)
  • Table 103. Italy Rare Disease Treatment, by Application USD Million (2013-2018)
  • Table 104. Italy Rare Disease Treatment, by Drug Type USD Million (2013-2018)
  • Table 105. Italy Rare Disease Treatment, by Distribution Channel USD Million (2013-2018)
  • Table 106. Italy Rare Disease Treatment, by Form USD Million (2013-2018)
  • Table 107. Italy Rare Disease Treatment, by Therapeutic Area USD Million (2013-2018)
  • Table 108. United Kingdom Rare Disease Treatment, by Application USD Million (2013-2018)
  • Table 109. United Kingdom Rare Disease Treatment, by Drug Type USD Million (2013-2018)
  • Table 110. United Kingdom Rare Disease Treatment, by Distribution Channel USD Million (2013-2018)
  • Table 111. United Kingdom Rare Disease Treatment, by Form USD Million (2013-2018)
  • Table 112. United Kingdom Rare Disease Treatment, by Therapeutic Area USD Million (2013-2018)
  • Table 113. Netherlands Rare Disease Treatment, by Application USD Million (2013-2018)
  • Table 114. Netherlands Rare Disease Treatment, by Drug Type USD Million (2013-2018)
  • Table 115. Netherlands Rare Disease Treatment, by Distribution Channel USD Million (2013-2018)
  • Table 116. Netherlands Rare Disease Treatment, by Form USD Million (2013-2018)
  • Table 117. Netherlands Rare Disease Treatment, by Therapeutic Area USD Million (2013-2018)
  • Table 118. Rest of Europe Rare Disease Treatment, by Application USD Million (2013-2018)
  • Table 119. Rest of Europe Rare Disease Treatment, by Drug Type USD Million (2013-2018)
  • Table 120. Rest of Europe Rare Disease Treatment, by Distribution Channel USD Million (2013-2018)
  • Table 121. Rest of Europe Rare Disease Treatment, by Form USD Million (2013-2018)
  • Table 122. Rest of Europe Rare Disease Treatment, by Therapeutic Area USD Million (2013-2018)
  • Table 123. MEA Rare Disease Treatment, by Country USD Million (2013-2018)
  • Table 124. MEA Rare Disease Treatment, by Application USD Million (2013-2018)
  • Table 125. MEA Rare Disease Treatment, by Drug Type USD Million (2013-2018)
  • Table 126. MEA Rare Disease Treatment, by Distribution Channel USD Million (2013-2018)
  • Table 127. MEA Rare Disease Treatment, by Form USD Million (2013-2018)
  • Table 128. MEA Rare Disease Treatment, by Therapeutic Area USD Million (2013-2018)
  • Table 129. Middle East Rare Disease Treatment, by Application USD Million (2013-2018)
  • Table 130. Middle East Rare Disease Treatment, by Drug Type USD Million (2013-2018)
  • Table 131. Middle East Rare Disease Treatment, by Distribution Channel USD Million (2013-2018)
  • Table 132. Middle East Rare Disease Treatment, by Form USD Million (2013-2018)
  • Table 133. Middle East Rare Disease Treatment, by Therapeutic Area USD Million (2013-2018)
  • Table 134. Africa Rare Disease Treatment, by Application USD Million (2013-2018)
  • Table 135. Africa Rare Disease Treatment, by Drug Type USD Million (2013-2018)
  • Table 136. Africa Rare Disease Treatment, by Distribution Channel USD Million (2013-2018)
  • Table 137. Africa Rare Disease Treatment, by Form USD Million (2013-2018)
  • Table 138. Africa Rare Disease Treatment, by Therapeutic Area USD Million (2013-2018)
  • Table 139. North America Rare Disease Treatment, by Country USD Million (2013-2018)
  • Table 140. North America Rare Disease Treatment, by Application USD Million (2013-2018)
  • Table 141. North America Rare Disease Treatment, by Drug Type USD Million (2013-2018)
  • Table 142. North America Rare Disease Treatment, by Distribution Channel USD Million (2013-2018)
  • Table 143. North America Rare Disease Treatment, by Form USD Million (2013-2018)
  • Table 144. North America Rare Disease Treatment, by Therapeutic Area USD Million (2013-2018)
  • Table 145. United States Rare Disease Treatment, by Application USD Million (2013-2018)
  • Table 146. United States Rare Disease Treatment, by Drug Type USD Million (2013-2018)
  • Table 147. United States Rare Disease Treatment, by Distribution Channel USD Million (2013-2018)
  • Table 148. United States Rare Disease Treatment, by Form USD Million (2013-2018)
  • Table 149. United States Rare Disease Treatment, by Therapeutic Area USD Million (2013-2018)
  • Table 150. Canada Rare Disease Treatment, by Application USD Million (2013-2018)
  • Table 151. Canada Rare Disease Treatment, by Drug Type USD Million (2013-2018)
  • Table 152. Canada Rare Disease Treatment, by Distribution Channel USD Million (2013-2018)
  • Table 153. Canada Rare Disease Treatment, by Form USD Million (2013-2018)
  • Table 154. Canada Rare Disease Treatment, by Therapeutic Area USD Million (2013-2018)
  • Table 155. Mexico Rare Disease Treatment, by Application USD Million (2013-2018)
  • Table 156. Mexico Rare Disease Treatment, by Drug Type USD Million (2013-2018)
  • Table 157. Mexico Rare Disease Treatment, by Distribution Channel USD Million (2013-2018)
  • Table 158. Mexico Rare Disease Treatment, by Form USD Million (2013-2018)
  • Table 159. Mexico Rare Disease Treatment, by Therapeutic Area USD Million (2013-2018)
  • Table 160. Rare Disease Treatment Sales: by Application(K Unit)
  • Table 161. Rare Disease Treatment Sales Hospitals , by Region K Unit (2013-2018)
  • Table 162. Rare Disease Treatment Sales Clinics , by Region K Unit (2013-2018)
  • Table 163. Rare Disease Treatment Sales Others , by Region K Unit (2013-2018)
  • Table 164. Rare Disease Treatment Sales: by Drug Type(K Unit)
  • Table 165. Rare Disease Treatment Sales Originator , by Region K Unit (2013-2018)
  • Table 166. Rare Disease Treatment Sales Generic , by Region K Unit (2013-2018)
  • Table 167. Rare Disease Treatment Sales: by Form(K Unit)
  • Table 168. Rare Disease Treatment Sales Tablet , by Region K Unit (2013-2018)
  • Table 169. Rare Disease Treatment Sales Powder , by Region K Unit (2013-2018)
  • Table 170. Rare Disease Treatment Sales Injections , by Region K Unit (2013-2018)
  • Table 171. Rare Disease Treatment Sales Others , by Region K Unit (2013-2018)
  • Table 172. Rare Disease Treatment Sales: by Therapeutic Area(K Unit)
  • Table 173. Rare Disease Treatment Sales Oncology , by Region K Unit (2013-2018)
  • Table 174. Rare Disease Treatment Sales Hematology , by Region K Unit (2013-2018)
  • Table 175. Rare Disease Treatment Sales Inflammatory Disease , by Region K Unit (2013-2018)
  • Table 176. Rare Disease Treatment Sales Endocrine Disease , by Region K Unit (2013-2018)
  • Table 177. Rare Disease Treatment Sales Metabolic Disease , by Region K Unit (2013-2018)
  • Table 178. Rare Disease Treatment Sales Infectious Disease , by Region K Unit (2013-2018)
  • Table 179. Rare Disease Treatment Sales Neurological Disease , by Region K Unit (2013-2018)
  • Table 180. Rare Disease Treatment Sales Skin Disease , by Region K Unit (2013-2018)
  • Table 181. Rare Disease Treatment Sales Pulmonary Disease , by Region K Unit (2013-2018)
  • Table 182. Rare Disease Treatment Sales Kidney Disease , by Region K Unit (2013-2018)
  • Table 183. Rare Disease Treatment Sales Musculoskeletal Disease , by Region K Unit (2013-2018)
  • Table 184. South America Rare Disease Treatment Sales, by Country K Unit (2013-2018)
  • Table 185. South America Rare Disease Treatment Sales, by Application K Unit (2013-2018)
  • Table 186. South America Rare Disease Treatment Sales, by Drug Type K Unit (2013-2018)
  • Table 187. South America Rare Disease Treatment Sales, by Distribution Channel K Unit (2013-2018)
  • Table 188. South America Rare Disease Treatment Sales, by Form K Unit (2013-2018)
  • Table 189. South America Rare Disease Treatment Sales, by Therapeutic Area K Unit (2013-2018)
  • Table 190. Brazil Rare Disease Treatment Sales, by Application K Unit (2013-2018)
  • Table 191. Brazil Rare Disease Treatment Sales, by Drug Type K Unit (2013-2018)
  • Table 192. Brazil Rare Disease Treatment Sales, by Distribution Channel K Unit (2013-2018)
  • Table 193. Brazil Rare Disease Treatment Sales, by Form K Unit (2013-2018)
  • Table 194. Brazil Rare Disease Treatment Sales, by Therapeutic Area K Unit (2013-2018)
  • Table 195. Argentina Rare Disease Treatment Sales, by Application K Unit (2013-2018)
  • Table 196. Argentina Rare Disease Treatment Sales, by Drug Type K Unit (2013-2018)
  • Table 197. Argentina Rare Disease Treatment Sales, by Distribution Channel K Unit (2013-2018)
  • Table 198. Argentina Rare Disease Treatment Sales, by Form K Unit (2013-2018)
  • Table 199. Argentina Rare Disease Treatment Sales, by Therapeutic Area K Unit (2013-2018)
  • Table 200. Rest of South America Rare Disease Treatment Sales, by Application K Unit (2013-2018)
  • Table 201. Rest of South America Rare Disease Treatment Sales, by Drug Type K Unit (2013-2018)
  • Table 202. Rest of South America Rare Disease Treatment Sales, by Distribution Channel K Unit (2013-2018)
  • Table 203. Rest of South America Rare Disease Treatment Sales, by Form K Unit (2013-2018)
  • Table 204. Rest of South America Rare Disease Treatment Sales, by Therapeutic Area K Unit (2013-2018)
  • Table 205. Asia Pacific Rare Disease Treatment Sales, by Country K Unit (2013-2018)
  • Table 206. Asia Pacific Rare Disease Treatment Sales, by Application K Unit (2013-2018)
  • Table 207. Asia Pacific Rare Disease Treatment Sales, by Drug Type K Unit (2013-2018)
  • Table 208. Asia Pacific Rare Disease Treatment Sales, by Distribution Channel K Unit (2013-2018)
  • Table 209. Asia Pacific Rare Disease Treatment Sales, by Form K Unit (2013-2018)
  • Table 210. Asia Pacific Rare Disease Treatment Sales, by Therapeutic Area K Unit (2013-2018)
  • Table 211. China Rare Disease Treatment Sales, by Application K Unit (2013-2018)
  • Table 212. China Rare Disease Treatment Sales, by Drug Type K Unit (2013-2018)
  • Table 213. China Rare Disease Treatment Sales, by Distribution Channel K Unit (2013-2018)
  • Table 214. China Rare Disease Treatment Sales, by Form K Unit (2013-2018)
  • Table 215. China Rare Disease Treatment Sales, by Therapeutic Area K Unit (2013-2018)
  • Table 216. Japan Rare Disease Treatment Sales, by Application K Unit (2013-2018)
  • Table 217. Japan Rare Disease Treatment Sales, by Drug Type K Unit (2013-2018)
  • Table 218. Japan Rare Disease Treatment Sales, by Distribution Channel K Unit (2013-2018)
  • Table 219. Japan Rare Disease Treatment Sales, by Form K Unit (2013-2018)
  • Table 220. Japan Rare Disease Treatment Sales, by Therapeutic Area K Unit (2013-2018)
  • Table 221. India Rare Disease Treatment Sales, by Application K Unit (2013-2018)
  • Table 222. India Rare Disease Treatment Sales, by Drug Type K Unit (2013-2018)
  • Table 223. India Rare Disease Treatment Sales, by Distribution Channel K Unit (2013-2018)
  • Table 224. India Rare Disease Treatment Sales, by Form K Unit (2013-2018)
  • Table 225. India Rare Disease Treatment Sales, by Therapeutic Area K Unit (2013-2018)
  • Table 226. South Korea Rare Disease Treatment Sales, by Application K Unit (2013-2018)
  • Table 227. South Korea Rare Disease Treatment Sales, by Drug Type K Unit (2013-2018)
  • Table 228. South Korea Rare Disease Treatment Sales, by Distribution Channel K Unit (2013-2018)
  • Table 229. South Korea Rare Disease Treatment Sales, by Form K Unit (2013-2018)
  • Table 230. South Korea Rare Disease Treatment Sales, by Therapeutic Area K Unit (2013-2018)
  • Table 231. Taiwan Rare Disease Treatment Sales, by Application K Unit (2013-2018)
  • Table 232. Taiwan Rare Disease Treatment Sales, by Drug Type K Unit (2013-2018)
  • Table 233. Taiwan Rare Disease Treatment Sales, by Distribution Channel K Unit (2013-2018)
  • Table 234. Taiwan Rare Disease Treatment Sales, by Form K Unit (2013-2018)
  • Table 235. Taiwan Rare Disease Treatment Sales, by Therapeutic Area K Unit (2013-2018)
  • Table 236. Australia Rare Disease Treatment Sales, by Application K Unit (2013-2018)
  • Table 237. Australia Rare Disease Treatment Sales, by Drug Type K Unit (2013-2018)
  • Table 238. Australia Rare Disease Treatment Sales, by Distribution Channel K Unit (2013-2018)
  • Table 239. Australia Rare Disease Treatment Sales, by Form K Unit (2013-2018)
  • Table 240. Australia Rare Disease Treatment Sales, by Therapeutic Area K Unit (2013-2018)
  • Table 241. Rest of Asia-Pacific Rare Disease Treatment Sales, by Application K Unit (2013-2018)
  • Table 242. Rest of Asia-Pacific Rare Disease Treatment Sales, by Drug Type K Unit (2013-2018)
  • Table 243. Rest of Asia-Pacific Rare Disease Treatment Sales, by Distribution Channel K Unit (2013-2018)
  • Table 244. Rest of Asia-Pacific Rare Disease Treatment Sales, by Form K Unit (2013-2018)
  • Table 245. Rest of Asia-Pacific Rare Disease Treatment Sales, by Therapeutic Area K Unit (2013-2018)
  • Table 246. Europe Rare Disease Treatment Sales, by Country K Unit (2013-2018)
  • Table 247. Europe Rare Disease Treatment Sales, by Application K Unit (2013-2018)
  • Table 248. Europe Rare Disease Treatment Sales, by Drug Type K Unit (2013-2018)
  • Table 249. Europe Rare Disease Treatment Sales, by Distribution Channel K Unit (2013-2018)
  • Table 250. Europe Rare Disease Treatment Sales, by Form K Unit (2013-2018)
  • Table 251. Europe Rare Disease Treatment Sales, by Therapeutic Area K Unit (2013-2018)
  • Table 252. Germany Rare Disease Treatment Sales, by Application K Unit (2013-2018)
  • Table 253. Germany Rare Disease Treatment Sales, by Drug Type K Unit (2013-2018)
  • Table 254. Germany Rare Disease Treatment Sales, by Distribution Channel K Unit (2013-2018)
  • Table 255. Germany Rare Disease Treatment Sales, by Form K Unit (2013-2018)
  • Table 256. Germany Rare Disease Treatment Sales, by Therapeutic Area K Unit (2013-2018)
  • Table 257. France Rare Disease Treatment Sales, by Application K Unit (2013-2018)
  • Table 258. France Rare Disease Treatment Sales, by Drug Type K Unit (2013-2018)
  • Table 259. France Rare Disease Treatment Sales, by Distribution Channel K Unit (2013-2018)
  • Table 260. France Rare Disease Treatment Sales, by Form K Unit (2013-2018)
  • Table 261. France Rare Disease Treatment Sales, by Therapeutic Area K Unit (2013-2018)
  • Table 262. Italy Rare Disease Treatment Sales, by Application K Unit (2013-2018)
  • Table 263. Italy Rare Disease Treatment Sales, by Drug Type K Unit (2013-2018)
  • Table 264. Italy Rare Disease Treatment Sales, by Distribution Channel K Unit (2013-2018)
  • Table 265. Italy Rare Disease Treatment Sales, by Form K Unit (2013-2018)
  • Table 266. Italy Rare Disease Treatment Sales, by Therapeutic Area K Unit (2013-2018)
  • Table 267. United Kingdom Rare Disease Treatment Sales, by Application K Unit (2013-2018)
  • Table 268. United Kingdom Rare Disease Treatment Sales, by Drug Type K Unit (2013-2018)
  • Table 269. United Kingdom Rare Disease Treatment Sales, by Distribution Channel K Unit (2013-2018)
  • Table 270. United Kingdom Rare Disease Treatment Sales, by Form K Unit (2013-2018)
  • Table 271. United Kingdom Rare Disease Treatment Sales, by Therapeutic Area K Unit (2013-2018)
  • Table 272. Netherlands Rare Disease Treatment Sales, by Application K Unit (2013-2018)
  • Table 273. Netherlands Rare Disease Treatment Sales, by Drug Type K Unit (2013-2018)
  • Table 274. Netherlands Rare Disease Treatment Sales, by Distribution Channel K Unit (2013-2018)
  • Table 275. Netherlands Rare Disease Treatment Sales, by Form K Unit (2013-2018)
  • Table 276. Netherlands Rare Disease Treatment Sales, by Therapeutic Area K Unit (2013-2018)
  • Table 277. Rest of Europe Rare Disease Treatment Sales, by Application K Unit (2013-2018)
  • Table 278. Rest of Europe Rare Disease Treatment Sales, by Drug Type K Unit (2013-2018)
  • Table 279. Rest of Europe Rare Disease Treatment Sales, by Distribution Channel K Unit (2013-2018)
  • Table 280. Rest of Europe Rare Disease Treatment Sales, by Form K Unit (2013-2018)
  • Table 281. Rest of Europe Rare Disease Treatment Sales, by Therapeutic Area K Unit (2013-2018)
  • Table 282. MEA Rare Disease Treatment Sales, by Country K Unit (2013-2018)
  • Table 283. MEA Rare Disease Treatment Sales, by Application K Unit (2013-2018)
  • Table 284. MEA Rare Disease Treatment Sales, by Drug Type K Unit (2013-2018)
  • Table 285. MEA Rare Disease Treatment Sales, by Distribution Channel K Unit (2013-2018)
  • Table 286. MEA Rare Disease Treatment Sales, by Form K Unit (2013-2018)
  • Table 287. MEA Rare Disease Treatment Sales, by Therapeutic Area K Unit (2013-2018)
  • Table 288. Middle East Rare Disease Treatment Sales, by Application K Unit (2013-2018)
  • Table 289. Middle East Rare Disease Treatment Sales, by Drug Type K Unit (2013-2018)
  • Table 290. Middle East Rare Disease Treatment Sales, by Distribution Channel K Unit (2013-2018)
  • Table 291. Middle East Rare Disease Treatment Sales, by Form K Unit (2013-2018)
  • Table 292. Middle East Rare Disease Treatment Sales, by Therapeutic Area K Unit (2013-2018)
  • Table 293. Africa Rare Disease Treatment Sales, by Application K Unit (2013-2018)
  • Table 294. Africa Rare Disease Treatment Sales, by Drug Type K Unit (2013-2018)
  • Table 295. Africa Rare Disease Treatment Sales, by Distribution Channel K Unit (2013-2018)
  • Table 296. Africa Rare Disease Treatment Sales, by Form K Unit (2013-2018)
  • Table 297. Africa Rare Disease Treatment Sales, by Therapeutic Area K Unit (2013-2018)
  • Table 298. North America Rare Disease Treatment Sales, by Country K Unit (2013-2018)
  • Table 299. North America Rare Disease Treatment Sales, by Application K Unit (2013-2018)
  • Table 300. North America Rare Disease Treatment Sales, by Drug Type K Unit (2013-2018)
  • Table 301. North America Rare Disease Treatment Sales, by Distribution Channel K Unit (2013-2018)
  • Table 302. North America Rare Disease Treatment Sales, by Form K Unit (2013-2018)
  • Table 303. North America Rare Disease Treatment Sales, by Therapeutic Area K Unit (2013-2018)
  • Table 304. United States Rare Disease Treatment Sales, by Application K Unit (2013-2018)
  • Table 305. United States Rare Disease Treatment Sales, by Drug Type K Unit (2013-2018)
  • Table 306. United States Rare Disease Treatment Sales, by Distribution Channel K Unit (2013-2018)
  • Table 307. United States Rare Disease Treatment Sales, by Form K Unit (2013-2018)
  • Table 308. United States Rare Disease Treatment Sales, by Therapeutic Area K Unit (2013-2018)
  • Table 309. Canada Rare Disease Treatment Sales, by Application K Unit (2013-2018)
  • Table 310. Canada Rare Disease Treatment Sales, by Drug Type K Unit (2013-2018)
  • Table 311. Canada Rare Disease Treatment Sales, by Distribution Channel K Unit (2013-2018)
  • Table 312. Canada Rare Disease Treatment Sales, by Form K Unit (2013-2018)
  • Table 313. Canada Rare Disease Treatment Sales, by Therapeutic Area K Unit (2013-2018)
  • Table 314. Mexico Rare Disease Treatment Sales, by Application K Unit (2013-2018)
  • Table 315. Mexico Rare Disease Treatment Sales, by Drug Type K Unit (2013-2018)
  • Table 316. Mexico Rare Disease Treatment Sales, by Distribution Channel K Unit (2013-2018)
  • Table 317. Mexico Rare Disease Treatment Sales, by Form K Unit (2013-2018)
  • Table 318. Mexico Rare Disease Treatment Sales, by Therapeutic Area K Unit (2013-2018)
  • Table 319. Company Basic Information, Sales Area and Its Competitors
  • Table 320. Company Basic Information, Sales Area and Its Competitors
  • Table 321. Company Basic Information, Sales Area and Its Competitors
  • Table 322. Company Basic Information, Sales Area and Its Competitors
  • Table 323. Company Basic Information, Sales Area and Its Competitors
  • Table 324. Company Basic Information, Sales Area and Its Competitors
  • Table 325. Company Basic Information, Sales Area and Its Competitors
  • Table 326. Company Basic Information, Sales Area and Its Competitors
  • Table 327. Company Basic Information, Sales Area and Its Competitors
  • Table 328. Company Basic Information, Sales Area and Its Competitors
  • Table 329. Company Basic Information, Sales Area and Its Competitors
  • Table 330. Company Basic Information, Sales Area and Its Competitors
  • Table 331. Company Basic Information, Sales Area and Its Competitors
  • Table 332. Company Basic Information, Sales Area and Its Competitors
  • Table 333. Company Basic Information, Sales Area and Its Competitors
  • Table 334. Rare Disease Treatment: by Application(USD Million)
  • Table 335. Rare Disease Treatment Hospitals , by Region USD Million (2019-2024)
  • Table 336. Rare Disease Treatment Clinics , by Region USD Million (2019-2024)
  • Table 337. Rare Disease Treatment Others , by Region USD Million (2019-2024)
  • Table 338. Rare Disease Treatment: by Drug Type(USD Million)
  • Table 339. Rare Disease Treatment Originator , by Region USD Million (2019-2024)
  • Table 340. Rare Disease Treatment Generic , by Region USD Million (2019-2024)
  • Table 341. Rare Disease Treatment: by Form(USD Million)
  • Table 342. Rare Disease Treatment Tablet , by Region USD Million (2019-2024)
  • Table 343. Rare Disease Treatment Powder , by Region USD Million (2019-2024)
  • Table 344. Rare Disease Treatment Injections , by Region USD Million (2019-2024)
  • Table 345. Rare Disease Treatment Others , by Region USD Million (2019-2024)
  • Table 346. Rare Disease Treatment: by Therapeutic Area(USD Million)
  • Table 347. Rare Disease Treatment Oncology , by Region USD Million (2019-2024)
  • Table 348. Rare Disease Treatment Hematology , by Region USD Million (2019-2024)
  • Table 349. Rare Disease Treatment Inflammatory Disease , by Region USD Million (2019-2024)
  • Table 350. Rare Disease Treatment Endocrine Disease , by Region USD Million (2019-2024)
  • Table 351. Rare Disease Treatment Metabolic Disease , by Region USD Million (2019-2024)
  • Table 352. Rare Disease Treatment Infectious Disease , by Region USD Million (2019-2024)
  • Table 353. Rare Disease Treatment Neurological Disease , by Region USD Million (2019-2024)
  • Table 354. Rare Disease Treatment Skin Disease , by Region USD Million (2019-2024)
  • Table 355. Rare Disease Treatment Pulmonary Disease , by Region USD Million (2019-2024)
  • Table 356. Rare Disease Treatment Kidney Disease , by Region USD Million (2019-2024)
  • Table 357. Rare Disease Treatment Musculoskeletal Disease , by Region USD Million (2019-2024)
  • Table 358. South America Rare Disease Treatment, by Country USD Million (2019-2024)
  • Table 359. South America Rare Disease Treatment, by Application USD Million (2019-2024)
  • Table 360. South America Rare Disease Treatment, by Drug Type USD Million (2019-2024)
  • Table 361. South America Rare Disease Treatment, by Distribution Channel USD Million (2019-2024)
  • Table 362. South America Rare Disease Treatment, by Form USD Million (2019-2024)
  • Table 363. South America Rare Disease Treatment, by Therapeutic Area USD Million (2019-2024)
  • Table 364. Brazil Rare Disease Treatment, by Application USD Million (2019-2024)
  • Table 365. Brazil Rare Disease Treatment, by Drug Type USD Million (2019-2024)
  • Table 366. Brazil Rare Disease Treatment, by Distribution Channel USD Million (2019-2024)
  • Table 367. Brazil Rare Disease Treatment, by Form USD Million (2019-2024)
  • Table 368. Brazil Rare Disease Treatment, by Therapeutic Area USD Million (2019-2024)
  • Table 369. Argentina Rare Disease Treatment, by Application USD Million (2019-2024)
  • Table 370. Argentina Rare Disease Treatment, by Drug Type USD Million (2019-2024)
  • Table 371. Argentina Rare Disease Treatment, by Distribution Channel USD Million (2019-2024)
  • Table 372. Argentina Rare Disease Treatment, by Form USD Million (2019-2024)
  • Table 373. Argentina Rare Disease Treatment, by Therapeutic Area USD Million (2019-2024)
  • Table 374. Rest of South America Rare Disease Treatment, by Application USD Million (2019-2024)
  • Table 375. Rest of South America Rare Disease Treatment, by Drug Type USD Million (2019-2024)
  • Table 376. Rest of South America Rare Disease Treatment, by Distribution Channel USD Million (2019-2024)
  • Table 377. Rest of South America Rare Disease Treatment, by Form USD Million (2019-2024)
  • Table 378. Rest of South America Rare Disease Treatment, by Therapeutic Area USD Million (2019-2024)
  • Table 379. Asia Pacific Rare Disease Treatment, by Country USD Million (2019-2024)
  • Table 380. Asia Pacific Rare Disease Treatment, by Application USD Million (2019-2024)
  • Table 381. Asia Pacific Rare Disease Treatment, by Drug Type USD Million (2019-2024)
  • Table 382. Asia Pacific Rare Disease Treatment, by Distribution Channel USD Million (2019-2024)
  • Table 383. Asia Pacific Rare Disease Treatment, by Form USD Million (2019-2024)
  • Table 384. Asia Pacific Rare Disease Treatment, by Therapeutic Area USD Million (2019-2024)
  • Table 385. China Rare Disease Treatment, by Application USD Million (2019-2024)
  • Table 386. China Rare Disease Treatment, by Drug Type USD Million (2019-2024)
  • Table 387. China Rare Disease Treatment, by Distribution Channel USD Million (2019-2024)
  • Table 388. China Rare Disease Treatment, by Form USD Million (2019-2024)
  • Table 389. China Rare Disease Treatment, by Therapeutic Area USD Million (2019-2024)
  • Table 390. Japan Rare Disease Treatment, by Application USD Million (2019-2024)
  • Table 391. Japan Rare Disease Treatment, by Drug Type USD Million (2019-2024)
  • Table 392. Japan Rare Disease Treatment, by Distribution Channel USD Million (2019-2024)
  • Table 393. Japan Rare Disease Treatment, by Form USD Million (2019-2024)
  • Table 394. Japan Rare Disease Treatment, by Therapeutic Area USD Million (2019-2024)
  • Table 395. India Rare Disease Treatment, by Application USD Million (2019-2024)
  • Table 396. India Rare Disease Treatment, by Drug Type USD Million (2019-2024)
  • Table 397. India Rare Disease Treatment, by Distribution Channel USD Million (2019-2024)
  • Table 398. India Rare Disease Treatment, by Form USD Million (2019-2024)
  • Table 399. India Rare Disease Treatment, by Therapeutic Area USD Million (2019-2024)
  • Table 400. South Korea Rare Disease Treatment, by Application USD Million (2019-2024)
  • Table 401. South Korea Rare Disease Treatment, by Drug Type USD Million (2019-2024)
  • Table 402. South Korea Rare Disease Treatment, by Distribution Channel USD Million (2019-2024)
  • Table 403. South Korea Rare Disease Treatment, by Form USD Million (2019-2024)
  • Table 404. South Korea Rare Disease Treatment, by Therapeutic Area USD Million (2019-2024)
  • Table 405. Taiwan Rare Disease Treatment, by Application USD Million (2019-2024)
  • Table 406. Taiwan Rare Disease Treatment, by Drug Type USD Million (2019-2024)
  • Table 407. Taiwan Rare Disease Treatment, by Distribution Channel USD Million (2019-2024)
  • Table 408. Taiwan Rare Disease Treatment, by Form USD Million (2019-2024)
  • Table 409. Taiwan Rare Disease Treatment, by Therapeutic Area USD Million (2019-2024)
  • Table 410. Australia Rare Disease Treatment, by Application USD Million (2019-2024)
  • Table 411. Australia Rare Disease Treatment, by Drug Type USD Million (2019-2024)
  • Table 412. Australia Rare Disease Treatment, by Distribution Channel USD Million (2019-2024)
  • Table 413. Australia Rare Disease Treatment, by Form USD Million (2019-2024)
  • Table 414. Australia Rare Disease Treatment, by Therapeutic Area USD Million (2019-2024)
  • Table 415. Rest of Asia-Pacific Rare Disease Treatment, by Application USD Million (2019-2024)
  • Table 416. Rest of Asia-Pacific Rare Disease Treatment, by Drug Type USD Million (2019-2024)
  • Table 417. Rest of Asia-Pacific Rare Disease Treatment, by Distribution Channel USD Million (2019-2024)
  • Table 418. Rest of Asia-Pacific Rare Disease Treatment, by Form USD Million (2019-2024)
  • Table 419. Rest of Asia-Pacific Rare Disease Treatment, by Therapeutic Area USD Million (2019-2024)
  • Table 420. Europe Rare Disease Treatment, by Country USD Million (2019-2024)
  • Table 421. Europe Rare Disease Treatment, by Application USD Million (2019-2024)
  • Table 422. Europe Rare Disease Treatment, by Drug Type USD Million (2019-2024)
  • Table 423. Europe Rare Disease Treatment, by Distribution Channel USD Million (2019-2024)
  • Table 424. Europe Rare Disease Treatment, by Form USD Million (2019-2024)
  • Table 425. Europe Rare Disease Treatment, by Therapeutic Area USD Million (2019-2024)
  • Table 426. Germany Rare Disease Treatment, by Application USD Million (2019-2024)
  • Table 427. Germany Rare Disease Treatment, by Drug Type USD Million (2019-2024)
  • Table 428. Germany Rare Disease Treatment, by Distribution Channel USD Million (2019-2024)
  • Table 429. Germany Rare Disease Treatment, by Form USD Million (2019-2024)
  • Table 430. Germany Rare Disease Treatment, by Therapeutic Area USD Million (2019-2024)
  • Table 431. France Rare Disease Treatment, by Application USD Million (2019-2024)
  • Table 432. France Rare Disease Treatment, by Drug Type USD Million (2019-2024)
  • Table 433. France Rare Disease Treatment, by Distribution Channel USD Million (2019-2024)
  • Table 434. France Rare Disease Treatment, by Form USD Million (2019-2024)
  • Table 435. France Rare Disease Treatment, by Therapeutic Area USD Million (2019-2024)
  • Table 436. Italy Rare Disease Treatment, by Application USD Million (2019-2024)
  • Table 437. Italy Rare Disease Treatment, by Drug Type USD Million (2019-2024)
  • Table 438. Italy Rare Disease Treatment, by Distribution Channel USD Million (2019-2024)
  • Table 439. Italy Rare Disease Treatment, by Form USD Million (2019-2024)
  • Table 440. Italy Rare Disease Treatment, by Therapeutic Area USD Million (2019-2024)
  • Table 441. United Kingdom Rare Disease Treatment, by Application USD Million (2019-2024)
  • Table 442. United Kingdom Rare Disease Treatment, by Drug Type USD Million (2019-2024)
  • Table 443. United Kingdom Rare Disease Treatment, by Distribution Channel USD Million (2019-2024)
  • Table 444. United Kingdom Rare Disease Treatment, by Form USD Million (2019-2024)
  • Table 445. United Kingdom Rare Disease Treatment, by Therapeutic Area USD Million (2019-2024)
  • Table 446. Netherlands Rare Disease Treatment, by Application USD Million (2019-2024)
  • Table 447. Netherlands Rare Disease Treatment, by Drug Type USD Million (2019-2024)
  • Table 448. Netherlands Rare Disease Treatment, by Distribution Channel USD Million (2019-2024)
  • Table 449. Netherlands Rare Disease Treatment, by Form USD Million (2019-2024)
  • Table 450. Netherlands Rare Disease Treatment, by Therapeutic Area USD Million (2019-2024)
  • Table 451. Rest of Europe Rare Disease Treatment, by Application USD Million (2019-2024)
  • Table 452. Rest of Europe Rare Disease Treatment, by Drug Type USD Million (2019-2024)
  • Table 453. Rest of Europe Rare Disease Treatment, by Distribution Channel USD Million (2019-2024)
  • Table 454. Rest of Europe Rare Disease Treatment, by Form USD Million (2019-2024)
  • Table 455. Rest of Europe Rare Disease Treatment, by Therapeutic Area USD Million (2019-2024)
  • Table 456. MEA Rare Disease Treatment, by Country USD Million (2019-2024)
  • Table 457. MEA Rare Disease Treatment, by Application USD Million (2019-2024)
  • Table 458. MEA Rare Disease Treatment, by Drug Type USD Million (2019-2024)
  • Table 459. MEA Rare Disease Treatment, by Distribution Channel USD Million (2019-2024)
  • Table 460. MEA Rare Disease Treatment, by Form USD Million (2019-2024)
  • Table 461. MEA Rare Disease Treatment, by Therapeutic Area USD Million (2019-2024)
  • Table 462. Middle East Rare Disease Treatment, by Application USD Million (2019-2024)
  • Table 463. Middle East Rare Disease Treatment, by Drug Type USD Million (2019-2024)
  • Table 464. Middle East Rare Disease Treatment, by Distribution Channel USD Million (2019-2024)
  • Table 465. Middle East Rare Disease Treatment, by Form USD Million (2019-2024)
  • Table 466. Middle East Rare Disease Treatment, by Therapeutic Area USD Million (2019-2024)
  • Table 467. Africa Rare Disease Treatment, by Application USD Million (2019-2024)
  • Table 468. Africa Rare Disease Treatment, by Drug Type USD Million (2019-2024)
  • Table 469. Africa Rare Disease Treatment, by Distribution Channel USD Million (2019-2024)
  • Table 470. Africa Rare Disease Treatment, by Form USD Million (2019-2024)
  • Table 471. Africa Rare Disease Treatment, by Therapeutic Area USD Million (2019-2024)
  • Table 472. North America Rare Disease Treatment, by Country USD Million (2019-2024)
  • Table 473. North America Rare Disease Treatment, by Application USD Million (2019-2024)
  • Table 474. North America Rare Disease Treatment, by Drug Type USD Million (2019-2024)
  • Table 475. North America Rare Disease Treatment, by Distribution Channel USD Million (2019-2024)
  • Table 476. North America Rare Disease Treatment, by Form USD Million (2019-2024)
  • Table 477. North America Rare Disease Treatment, by Therapeutic Area USD Million (2019-2024)
  • Table 478. United States Rare Disease Treatment, by Application USD Million (2019-2024)
  • Table 479. United States Rare Disease Treatment, by Drug Type USD Million (2019-2024)
  • Table 480. United States Rare Disease Treatment, by Distribution Channel USD Million (2019-2024)
  • Table 481. United States Rare Disease Treatment, by Form USD Million (2019-2024)
  • Table 482. United States Rare Disease Treatment, by Therapeutic Area USD Million (2019-2024)
  • Table 483. Canada Rare Disease Treatment, by Application USD Million (2019-2024)
  • Table 484. Canada Rare Disease Treatment, by Drug Type USD Million (2019-2024)
  • Table 485. Canada Rare Disease Treatment, by Distribution Channel USD Million (2019-2024)
  • Table 486. Canada Rare Disease Treatment, by Form USD Million (2019-2024)
  • Table 487. Canada Rare Disease Treatment, by Therapeutic Area USD Million (2019-2024)
  • Table 488. Mexico Rare Disease Treatment, by Application USD Million (2019-2024)
  • Table 489. Mexico Rare Disease Treatment, by Drug Type USD Million (2019-2024)
  • Table 490. Mexico Rare Disease Treatment, by Distribution Channel USD Million (2019-2024)
  • Table 491. Mexico Rare Disease Treatment, by Form USD Million (2019-2024)
  • Table 492. Mexico Rare Disease Treatment, by Therapeutic Area USD Million (2019-2024)
  • Table 493. Rare Disease Treatment Sales: by Application(K Unit)
  • Table 494. Rare Disease Treatment Sales Hospitals , by Region K Unit (2019-2024)
  • Table 495. Rare Disease Treatment Sales Clinics , by Region K Unit (2019-2024)
  • Table 496. Rare Disease Treatment Sales Others , by Region K Unit (2019-2024)
  • Table 497. Rare Disease Treatment Sales: by Drug Type(K Unit)
  • Table 498. Rare Disease Treatment Sales Originator , by Region K Unit (2019-2024)
  • Table 499. Rare Disease Treatment Sales Generic , by Region K Unit (2019-2024)
  • Table 500. Rare Disease Treatment Sales: by Form(K Unit)
  • Table 501. Rare Disease Treatment Sales Tablet , by Region K Unit (2019-2024)
  • Table 502. Rare Disease Treatment Sales Powder , by Region K Unit (2019-2024)
  • Table 503. Rare Disease Treatment Sales Injections , by Region K Unit (2019-2024)
  • Table 504. Rare Disease Treatment Sales Others , by Region K Unit (2019-2024)
  • Table 505. Rare Disease Treatment Sales: by Therapeutic Area(K Unit)
  • Table 506. Rare Disease Treatment Sales Oncology , by Region K Unit (2019-2024)
  • Table 507. Rare Disease Treatment Sales Hematology , by Region K Unit (2019-2024)
  • Table 508. Rare Disease Treatment Sales Inflammatory Disease , by Region K Unit (2019-2024)
  • Table 509. Rare Disease Treatment Sales Endocrine Disease , by Region K Unit (2019-2024)
  • Table 510. Rare Disease Treatment Sales Metabolic Disease , by Region K Unit (2019-2024)
  • Table 511. Rare Disease Treatment Sales Infectious Disease , by Region K Unit (2019-2024)
  • Table 512. Rare Disease Treatment Sales Neurological Disease , by Region K Unit (2019-2024)
  • Table 513. Rare Disease Treatment Sales Skin Disease , by Region K Unit (2019-2024)
  • Table 514. Rare Disease Treatment Sales Pulmonary Disease , by Region K Unit (2019-2024)
  • Table 515. Rare Disease Treatment Sales Kidney Disease , by Region K Unit (2019-2024)
  • Table 516. Rare Disease Treatment Sales Musculoskeletal Disease , by Region K Unit (2019-2024)
  • Table 517. South America Rare Disease Treatment Sales, by Country K Unit (2019-2024)
  • Table 518. South America Rare Disease Treatment Sales, by Application K Unit (2019-2024)
  • Table 519. South America Rare Disease Treatment Sales, by Drug Type K Unit (2019-2024)
  • Table 520. South America Rare Disease Treatment Sales, by Distribution Channel K Unit (2019-2024)
  • Table 521. South America Rare Disease Treatment Sales, by Form K Unit (2019-2024)
  • Table 522. South America Rare Disease Treatment Sales, by Therapeutic Area K Unit (2019-2024)
  • Table 523. Brazil Rare Disease Treatment Sales, by Application K Unit (2019-2024)
  • Table 524. Brazil Rare Disease Treatment Sales, by Drug Type K Unit (2019-2024)
  • Table 525. Brazil Rare Disease Treatment Sales, by Distribution Channel K Unit (2019-2024)
  • Table 526. Brazil Rare Disease Treatment Sales, by Form K Unit (2019-2024)
  • Table 527. Brazil Rare Disease Treatment Sales, by Therapeutic Area K Unit (2019-2024)
  • Table 528. Argentina Rare Disease Treatment Sales, by Application K Unit (2019-2024)
  • Table 529. Argentina Rare Disease Treatment Sales, by Drug Type K Unit (2019-2024)
  • Table 530. Argentina Rare Disease Treatment Sales, by Distribution Channel K Unit (2019-2024)
  • Table 531. Argentina Rare Disease Treatment Sales, by Form K Unit (2019-2024)
  • Table 532. Argentina Rare Disease Treatment Sales, by Therapeutic Area K Unit (2019-2024)
  • Table 533. Rest of South America Rare Disease Treatment Sales, by Application K Unit (2019-2024)
  • Table 534. Rest of South America Rare Disease Treatment Sales, by Drug Type K Unit (2019-2024)
  • Table 535. Rest of South America Rare Disease Treatment Sales, by Distribution Channel K Unit (2019-2024)
  • Table 536. Rest of South America Rare Disease Treatment Sales, by Form K Unit (2019-2024)
  • Table 537. Rest of South America Rare Disease Treatment Sales, by Therapeutic Area K Unit (2019-2024)
  • Table 538. Asia Pacific Rare Disease Treatment Sales, by Country K Unit (2019-2024)
  • Table 539. Asia Pacific Rare Disease Treatment Sales, by Application K Unit (2019-2024)
  • Table 540. Asia Pacific Rare Disease Treatment Sales, by Drug Type K Unit (2019-2024)
  • Table 541. Asia Pacific Rare Disease Treatment Sales, by Distribution Channel K Unit (2019-2024)
  • Table 542. Asia Pacific Rare Disease Treatment Sales, by Form K Unit (2019-2024)
  • Table 543. Asia Pacific Rare Disease Treatment Sales, by Therapeutic Area K Unit (2019-2024)
  • Table 544. China Rare Disease Treatment Sales, by Application K Unit (2019-2024)
  • Table 545. China Rare Disease Treatment Sales, by Drug Type K Unit (2019-2024)
  • Table 546. China Rare Disease Treatment Sales, by Distribution Channel K Unit (2019-2024)
  • Table 547. China Rare Disease Treatment Sales, by Form K Unit (2019-2024)
  • Table 548. China Rare Disease Treatment Sales, by Therapeutic Area K Unit (2019-2024)
  • Table 549. Japan Rare Disease Treatment Sales, by Application K Unit (2019-2024)
  • Table 550. Japan Rare Disease Treatment Sales, by Drug Type K Unit (2019-2024)
  • Table 551. Japan Rare Disease Treatment Sales, by Distribution Channel K Unit (2019-2024)
  • Table 552. Japan Rare Disease Treatment Sales, by Form K Unit (2019-2024)
  • Table 553. Japan Rare Disease Treatment Sales, by Therapeutic Area K Unit (2019-2024)
  • Table 554. India Rare Disease Treatment Sales, by Application K Unit (2019-2024)
  • Table 555. India Rare Disease Treatment Sales, by Drug Type K Unit (2019-2024)
  • Table 556. India Rare Disease Treatment Sales, by Distribution Channel K Unit (2019-2024)
  • Table 557. India Rare Disease Treatment Sales, by Form K Unit (2019-2024)
  • Table 558. India Rare Disease Treatment Sales, by Therapeutic Area K Unit (2019-2024)
  • Table 559. South Korea Rare Disease Treatment Sales, by Application K Unit (2019-2024)
  • Table 560. South Korea Rare Disease Treatment Sales, by Drug Type K Unit (2019-2024)
  • Table 561. South Korea Rare Disease Treatment Sales, by Distribution Channel K Unit (2019-2024)
  • Table 562. South Korea Rare Disease Treatment Sales, by Form K Unit (2019-2024)
  • Table 563. South Korea Rare Disease Treatment Sales, by Therapeutic Area K Unit (2019-2024)
  • Table 564. Taiwan Rare Disease Treatment Sales, by Application K Unit (2019-2024)
  • Table 565. Taiwan Rare Disease Treatment Sales, by Drug Type K Unit (2019-2024)
  • Table 566. Taiwan Rare Disease Treatment Sales, by Distribution Channel K Unit (2019-2024)
  • Table 567. Taiwan Rare Disease Treatment Sales, by Form K Unit (2019-2024)
  • Table 568. Taiwan Rare Disease Treatment Sales, by Therapeutic Area K Unit (2019-2024)
  • Table 569. Australia Rare Disease Treatment Sales, by Application K Unit (2019-2024)
  • Table 570. Australia Rare Disease Treatment Sales, by Drug Type K Unit (2019-2024)
  • Table 571. Australia Rare Disease Treatment Sales, by Distribution Channel K Unit (2019-2024)
  • Table 572. Australia Rare Disease Treatment Sales, by Form K Unit (2019-2024)
  • Table 573. Australia Rare Disease Treatment Sales, by Therapeutic Area K Unit (2019-2024)
  • Table 574. Rest of Asia-Pacific Rare Disease Treatment Sales, by Application K Unit (2019-2024)
  • Table 575. Rest of Asia-Pacific Rare Disease Treatment Sales, by Drug Type K Unit (2019-2024)
  • Table 576. Rest of Asia-Pacific Rare Disease Treatment Sales, by Distribution Channel K Unit (2019-2024)
  • Table 577. Rest of Asia-Pacific Rare Disease Treatment Sales, by Form K Unit (2019-2024)
  • Table 578. Rest of Asia-Pacific Rare Disease Treatment Sales, by Therapeutic Area K Unit (2019-2024)
  • Table 579. Europe Rare Disease Treatment Sales, by Country K Unit (2019-2024)
  • Table 580. Europe Rare Disease Treatment Sales, by Application K Unit (2019-2024)
  • Table 581. Europe Rare Disease Treatment Sales, by Drug Type K Unit (2019-2024)
  • Table 582. Europe Rare Disease Treatment Sales, by Distribution Channel K Unit (2019-2024)
  • Table 583. Europe Rare Disease Treatment Sales, by Form K Unit (2019-2024)
  • Table 584. Europe Rare Disease Treatment Sales, by Therapeutic Area K Unit (2019-2024)
  • Table 585. Germany Rare Disease Treatment Sales, by Application K Unit (2019-2024)
  • Table 586. Germany Rare Disease Treatment Sales, by Drug Type K Unit (2019-2024)
  • Table 587. Germany Rare Disease Treatment Sales, by Distribution Channel K Unit (2019-2024)
  • Table 588. Germany Rare Disease Treatment Sales, by Form K Unit (2019-2024)
  • Table 589. Germany Rare Disease Treatment Sales, by Therapeutic Area K Unit (2019-2024)
  • Table 590. France Rare Disease Treatment Sales, by Application K Unit (2019-2024)
  • Table 591. France Rare Disease Treatment Sales, by Drug Type K Unit (2019-2024)
  • Table 592. France Rare Disease Treatment Sales, by Distribution Channel K Unit (2019-2024)
  • Table 593. France Rare Disease Treatment Sales, by Form K Unit (2019-2024)
  • Table 594. France Rare Disease Treatment Sales, by Therapeutic Area K Unit (2019-2024)
  • Table 595. Italy Rare Disease Treatment Sales, by Application K Unit (2019-2024)
  • Table 596. Italy Rare Disease Treatment Sales, by Drug Type K Unit (2019-2024)
  • Table 597. Italy Rare Disease Treatment Sales, by Distribution Channel K Unit (2019-2024)
  • Table 598. Italy Rare Disease Treatment Sales, by Form K Unit (2019-2024)
  • Table 599. Italy Rare Disease Treatment Sales, by Therapeutic Area K Unit (2019-2024)
  • Table 600. United Kingdom Rare Disease Treatment Sales, by Application K Unit (2019-2024)
  • Table 601. United Kingdom Rare Disease Treatment Sales, by Drug Type K Unit (2019-2024)
  • Table 602. United Kingdom Rare Disease Treatment Sales, by Distribution Channel K Unit (2019-2024)
  • Table 603. United Kingdom Rare Disease Treatment Sales, by Form K Unit (2019-2024)
  • Table 604. United Kingdom Rare Disease Treatment Sales, by Therapeutic Area K Unit (2019-2024)
  • Table 605. Netherlands Rare Disease Treatment Sales, by Application K Unit (2019-2024)
  • Table 606. Netherlands Rare Disease Treatment Sales, by Drug Type K Unit (2019-2024)
  • Table 607. Netherlands Rare Disease Treatment Sales, by Distribution Channel K Unit (2019-2024)
  • Table 608. Netherlands Rare Disease Treatment Sales, by Form K Unit (2019-2024)
  • Table 609. Netherlands Rare Disease Treatment Sales, by Therapeutic Area K Unit (2019-2024)
  • Table 610. Rest of Europe Rare Disease Treatment Sales, by Application K Unit (2019-2024)
  • Table 611. Rest of Europe Rare Disease Treatment Sales, by Drug Type K Unit (2019-2024)
  • Table 612. Rest of Europe Rare Disease Treatment Sales, by Distribution Channel K Unit (2019-2024)
  • Table 613. Rest of Europe Rare Disease Treatment Sales, by Form K Unit (2019-2024)
  • Table 614. Rest of Europe Rare Disease Treatment Sales, by Therapeutic Area K Unit (2019-2024)
  • Table 615. MEA Rare Disease Treatment Sales, by Country K Unit (2019-2024)
  • Table 616. MEA Rare Disease Treatment Sales, by Application K Unit (2019-2024)
  • Table 617. MEA Rare Disease Treatment Sales, by Drug Type K Unit (2019-2024)
  • Table 618. MEA Rare Disease Treatment Sales, by Distribution Channel K Unit (2019-2024)
  • Table 619. MEA Rare Disease Treatment Sales, by Form K Unit (2019-2024)
  • Table 620. MEA Rare Disease Treatment Sales, by Therapeutic Area K Unit (2019-2024)
  • Table 621. Middle East Rare Disease Treatment Sales, by Application K Unit (2019-2024)
  • Table 622. Middle East Rare Disease Treatment Sales, by Drug Type K Unit (2019-2024)
  • Table 623. Middle East Rare Disease Treatment Sales, by Distribution Channel K Unit (2019-2024)
  • Table 624. Middle East Rare Disease Treatment Sales, by Form K Unit (2019-2024)
  • Table 625. Middle East Rare Disease Treatment Sales, by Therapeutic Area K Unit (2019-2024)
  • Table 626. Africa Rare Disease Treatment Sales, by Application K Unit (2019-2024)
  • Table 627. Africa Rare Disease Treatment Sales, by Drug Type K Unit (2019-2024)
  • Table 628. Africa Rare Disease Treatment Sales, by Distribution Channel K Unit (2019-2024)
  • Table 629. Africa Rare Disease Treatment Sales, by Form K Unit (2019-2024)
  • Table 630. Africa Rare Disease Treatment Sales, by Therapeutic Area K Unit (2019-2024)
  • Table 631. North America Rare Disease Treatment Sales, by Country K Unit (2019-2024)
  • Table 632. North America Rare Disease Treatment Sales, by Application K Unit (2019-2024)
  • Table 633. North America Rare Disease Treatment Sales, by Drug Type K Unit (2019-2024)
  • Table 634. North America Rare Disease Treatment Sales, by Distribution Channel K Unit (2019-2024)
  • Table 635. North America Rare Disease Treatment Sales, by Form K Unit (2019-2024)
  • Table 636. North America Rare Disease Treatment Sales, by Therapeutic Area K Unit (2019-2024)
  • Table 637. United States Rare Disease Treatment Sales, by Application K Unit (2019-2024)
  • Table 638. United States Rare Disease Treatment Sales, by Drug Type K Unit (2019-2024)
  • Table 639. United States Rare Disease Treatment Sales, by Distribution Channel K Unit (2019-2024)
  • Table 640. United States Rare Disease Treatment Sales, by Form K Unit (2019-2024)
  • Table 641. United States Rare Disease Treatment Sales, by Therapeutic Area K Unit (2019-2024)
  • Table 642. Canada Rare Disease Treatment Sales, by Application K Unit (2019-2024)
  • Table 643. Canada Rare Disease Treatment Sales, by Drug Type K Unit (2019-2024)
  • Table 644. Canada Rare Disease Treatment Sales, by Distribution Channel K Unit (2019-2024)
  • Table 645. Canada Rare Disease Treatment Sales, by Form K Unit (2019-2024)
  • Table 646. Canada Rare Disease Treatment Sales, by Therapeutic Area K Unit (2019-2024)
  • Table 647. Mexico Rare Disease Treatment Sales, by Application K Unit (2019-2024)
  • Table 648. Mexico Rare Disease Treatment Sales, by Drug Type K Unit (2019-2024)
  • Table 649. Mexico Rare Disease Treatment Sales, by Distribution Channel K Unit (2019-2024)
  • Table 650. Mexico Rare Disease Treatment Sales, by Form K Unit (2019-2024)
  • Table 651. Mexico Rare Disease Treatment Sales, by Therapeutic Area K Unit (2019-2024)
  • Table 652. Research Programs/Design for This Report
  • Table 653. Key Data Information from Secondary Sources
  • Table 654. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Rare Disease Treatment: by Application USD Million (2013-2018)
  • Figure 5. Global Rare Disease Treatment: by Drug Type USD Million (2013-2018)
  • Figure 6. Global Rare Disease Treatment: by Form USD Million (2013-2018)
  • Figure 7. Global Rare Disease Treatment: by Therapeutic Area USD Million (2013-2018)
  • Figure 8. South America Rare Disease Treatment Share (%), by Country
  • Figure 9. Asia Pacific Rare Disease Treatment Share (%), by Country
  • Figure 10. Europe Rare Disease Treatment Share (%), by Country
  • Figure 11. MEA Rare Disease Treatment Share (%), by Country
  • Figure 12. North America Rare Disease Treatment Share (%), by Country
  • Figure 13. Global Rare Disease Treatment: by Application K Unit (2013-2018)
  • Figure 14. Global Rare Disease Treatment: by Drug Type K Unit (2013-2018)
  • Figure 15. Global Rare Disease Treatment: by Form K Unit (2013-2018)
  • Figure 16. Global Rare Disease Treatment: by Therapeutic Area K Unit (2013-2018)
  • Figure 17. South America Rare Disease Treatment Share (%), by Country
  • Figure 18. Asia Pacific Rare Disease Treatment Share (%), by Country
  • Figure 19. Europe Rare Disease Treatment Share (%), by Country
  • Figure 20. MEA Rare Disease Treatment Share (%), by Country
  • Figure 21. North America Rare Disease Treatment Share (%), by Country
  • Figure 22. Global Rare Disease Treatment share by Players 2018 (%)
  • Figure 23. Global Rare Disease Treatment share by Players (Top 3) 2018(%)
  • Figure 24. Global Rare Disease Treatment share by Players (Top 5) 2018(%)
  • Figure 25. BCG Matrix for key Companies
  • Figure 26. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 27. Novartis (Switzerland) Revenue: by Geography 2018
  • Figure 28. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Pfizer, Inc. (United States) Revenue: by Geography 2018
  • Figure 30. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 31. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2018
  • Figure 32. Celgene Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 33. Celgene Corporation (United States) Revenue: by Geography 2018
  • Figure 34. Alexion Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Alexion Pharmaceuticals, Inc. (United States) Revenue: by Geography 2018
  • Figure 36. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 37. Johnson & Johnson (United States) Revenue: by Geography 2018
  • Figure 38. Novo Nordisk A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 39. Novo Nordisk A/S (Denmark) Revenue: by Geography 2018
  • Figure 40. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 41. Sanofi S.A. (France) Revenue: by Geography 2018
  • Figure 42. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 43. Bayer AG (Germany) Revenue: by Geography 2018
  • Figure 44. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 45. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2018
  • Figure 46. Allergan (Ireland) Revenue, Net Income and Gross profit
  • Figure 47. Allergan (Ireland) Revenue: by Geography 2018
  • Figure 48. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 49. Eli Lilly and Company (United States) Revenue: by Geography 2018
  • Figure 50. Eisai Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 51. Eisai Co., Ltd. (Japan) Revenue: by Geography 2018
  • Figure 52. Bristol-Myers Squibb Revenue, Net Income and Gross profit
  • Figure 53. Bristol-Myers Squibb Revenue: by Geography 2018
  • Figure 54. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 55. Merck & Co., Inc. (United States) Revenue: by Geography 2018
  • Figure 56. Global Rare Disease Treatment: by Application USD Million (2019-2024)
  • Figure 57. Global Rare Disease Treatment: by Drug Type USD Million (2019-2024)
  • Figure 58. Global Rare Disease Treatment: by Form USD Million (2019-2024)
  • Figure 59. Global Rare Disease Treatment: by Therapeutic Area USD Million (2019-2024)
  • Figure 60. South America Rare Disease Treatment Share (%), by Country
  • Figure 61. Asia Pacific Rare Disease Treatment Share (%), by Country
  • Figure 62. Europe Rare Disease Treatment Share (%), by Country
  • Figure 63. MEA Rare Disease Treatment Share (%), by Country
  • Figure 64. North America Rare Disease Treatment Share (%), by Country
  • Figure 65. Global Rare Disease Treatment: by Application K Unit (2019-2024)
  • Figure 66. Global Rare Disease Treatment: by Drug Type K Unit (2019-2024)
  • Figure 67. Global Rare Disease Treatment: by Form K Unit (2019-2024)
  • Figure 68. Global Rare Disease Treatment: by Therapeutic Area K Unit (2019-2024)
  • Figure 69. South America Rare Disease Treatment Share (%), by Country
  • Figure 70. Asia Pacific Rare Disease Treatment Share (%), by Country
  • Figure 71. Europe Rare Disease Treatment Share (%), by Country
  • Figure 72. MEA Rare Disease Treatment Share (%), by Country
  • Figure 73. North America Rare Disease Treatment Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Novartis (Switzerland)
  • Pfizer, Inc. (United States)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Celgene Corporation (United States)
  • Alexion Pharmaceuticals, Inc. (United States)
  • Johnson & Johnson (United States)
  • Novo Nordisk A/S (Denmark)
  • Sanofi S.A. (France)
  • Bayer AG (Germany)
  • GlaxoSmithKline (United Kingdom)
  • Allergan (Ireland)
  • Eli Lilly and Company (United States)
  • Eisai Co., Ltd. (Japan)
  • Bristol-Myers Squibb
  • Merck & Co., Inc. (United States)
Additional players considered in the study are as follows:
Bristol-Myers Squibb Company (United States) , AstraZeneca (United Kingdom) , Daiichi Sankyo Company Limited (Japan) , Biogen, Inc. (United States) , Shire Plc (United States) , Alexion Pharmaceuticals (United States) , Amgen Inc. (United States) , Vertex Pharmaceuticals (United States) , Baxter International Inc.. (United States) , BioMarin (United States) , Teva Pharmaceutical Industries (Isreal)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation